Synergy Innovation Co. Ltd - Asset Resilience Ratio
Synergy Innovation Co. Ltd (048870) has an Asset Resilience Ratio of 18.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Synergy Innovation Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Synergy Innovation Co. Ltd's Asset Resilience Ratio has changed over time. See 048870 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Synergy Innovation Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Synergy Innovation Co. Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩61.74 Billion | 18.41% |
| Total Liquid Assets | ₩61.74 Billion | 18.41% |
Asset Resilience Insights
- Good Liquidity Position: Synergy Innovation Co. Ltd maintains a healthy 18.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Synergy Innovation Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Synergy Innovation Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Synergy Innovation Co. Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Synergy Innovation Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.16% | ₩35.05 Billion ≈ $23.75 Million |
₩314.06 Billion ≈ $212.83 Million |
-3.77pp |
| 2023-12-31 | 14.93% | ₩42.69 Billion ≈ $28.93 Million |
₩285.90 Billion ≈ $193.75 Million |
+13.77pp |
| 2022-12-31 | 1.16% | ₩2.64 Billion ≈ $1.79 Million |
₩227.38 Billion ≈ $154.09 Million |
-15.05pp |
| 2021-12-31 | 16.21% | ₩32.85 Billion ≈ $22.26 Million |
₩202.70 Billion ≈ $137.37 Million |
-0.47pp |
| 2020-12-31 | 16.68% | ₩26.40 Billion ≈ $17.89 Million |
₩158.31 Billion ≈ $107.29 Million |
+7.04pp |
| 2019-12-31 | 9.64% | ₩14.20 Billion ≈ $9.62 Million |
₩147.29 Billion ≈ $99.82 Million |
-12.96pp |
| 2018-12-31 | 22.60% | ₩27.57 Billion ≈ $18.69 Million |
₩122.01 Billion ≈ $82.68 Million |
+15.07pp |
| 2017-12-31 | 7.53% | ₩7.98 Billion ≈ $5.41 Million |
₩106.06 Billion ≈ $71.87 Million |
-2.99pp |
| 2016-12-31 | 10.52% | ₩6.27 Billion ≈ $4.25 Million |
₩59.67 Billion ≈ $40.44 Million |
+6.68pp |
| 2015-12-31 | 3.83% | ₩616.99 Million ≈ $418.12K |
₩16.10 Billion ≈ $10.91 Million |
-16.76pp |
| 2014-12-31 | 20.59% | ₩16.90 Billion ≈ $11.45 Million |
₩82.08 Billion ≈ $55.62 Million |
+3.10pp |
| 2013-12-31 | 17.49% | ₩16.89 Billion ≈ $11.44 Million |
₩96.56 Billion ≈ $65.44 Million |
+5.28pp |
| 2012-12-31 | 12.21% | ₩15.90 Billion ≈ $10.77 Million |
₩130.20 Billion ≈ $88.24 Million |
-11.71pp |
| 2011-12-31 | 23.92% | ₩30.15 Billion ≈ $20.43 Million |
₩126.03 Billion ≈ $85.41 Million |
+1.75pp |
| 2009-12-31 | 22.17% | ₩31.70 Billion ≈ $21.48 Million |
₩143.00 Billion ≈ $96.91 Million |
-25.34pp |
| 2008-12-31 | 47.51% | ₩85.27 Billion ≈ $57.78 Million |
₩179.47 Billion ≈ $121.63 Million |
-2.02pp |
| 2007-12-31 | 49.53% | ₩77.56 Billion ≈ $52.56 Million |
₩156.60 Billion ≈ $106.13 Million |
+24.85pp |
| 2006-12-31 | 24.67% | ₩33.75 Billion ≈ $22.87 Million |
₩136.78 Billion ≈ $92.69 Million |
-- |
About Synergy Innovation Co. Ltd
Synergy Innovation Co., Ltd. engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea. It produces and sells various culture media for hospitals, pharmaceuticals, and food/cosmetics; manufactures synergy innovation " universal transport solutions (SI-UTS); and invests and develops in various fields comprising mic… Read more